Gastrointestinal Neoplasms  >>  Caprelsa (vandetanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
NCT00454116 / 2006-005023-42: A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

Completed
2
106
US, Europe, RoW
Vandetanib, ZD6474, ZACTIMA™, FOLFIRI
Genzyme, a Sanofi Company
Colorectal Cancer
03/08
11/09
NCT00500292 / 2006-005022-23: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

Completed
2
109
Europe, RoW
Vandetanib, AZ6474, ZACTIMA™, SAR390530, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Genzyme, a Sanofi Company
Colorectal, Cancer
03/08
11/16
NCT00508001: Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)

Checkmark P2 data (HCC)
Jan 2012 - Jan 2012: P2 data (HCC)
Completed
2
67
RoW
Vandetanib, Zactima, ZD6474, Best Supportive Care
Genzyme, a Sanofi Company
Carcinoma, Hepatocellular
11/08
06/09
VANGOGH, NCT00753675 / 2007-003056-12: Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer

Completed
2
174
Europe
ZD6474, Vandetanib, Zactima, Gemcitabine, Gemzar, Placebo matching ZD6474
Genzyme, a Sanofi Company
Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma
09/12
09/12

Download Options